The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.
Compared with placebo, alendronate treatment resulted in a significant protection against bone loss in healthy perimenopausal women. This protection occurred at both the spine and the hip and was evident after 6 months of therapy.